Carregant...
Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition
The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to...
Guardat en:
| Publicat a: | Brain Commun |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7425526/ https://ncbi.nlm.nih.gov/pubmed/32954282 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/braincomms/fcaa021 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|